Research programme: anticancer prodrug technology - Alexion Antibody Technologies
Latest Information Update: 25 Sep 2006
At a glance
- Originator The Scripps Research Institute
- Developer Alexion Antibody Technologies; Centocor; The Scripps Research Institute
- Class Catalytic antibodies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 13 Jun 2002 This programme is still in active development
- 06 Mar 2000 Preclinical development for Cancer in USA (Unknown route)